PARP inhibition elicits anti-tumour activity in BRCA-mutant HR-deficient cancers [9–14], due to the dependency of these cancers on PARP1 activity in SSB repair to avoid replication-dependent accumulation of DSBs. The gene discussed is PARP1; the disease is cancer.